ZA200701972B - Phenyl diazepane carboxamides and annelated phenyl piperazine carboxamides containing oxygen and used as dopamine D3 antagonists - Google Patents

Phenyl diazepane carboxamides and annelated phenyl piperazine carboxamides containing oxygen and used as dopamine D3 antagonists Download PDF

Info

Publication number: ZA200701972B
Authority: ZA; South Africa
Prior art keywords: ylcarbamide; butyl; piperazine; benzo; thiophene
Prior art date: 2004-12-30

Application number

ZA200701972A

Other languages

English (en)

Inventor

Gmeiner Peter

Hubner Harald

Schlotter Karin

Original Assignee

Sanol Arznei Schwarz Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-12-30

Filing date

2007-01-18

Publication date

2008-04-30

2007-01-18 Application filed by Sanol Arznei Schwarz Gmbh filed Critical Sanol Arznei Schwarz Gmbh

2008-04-30 Publication of ZA200701972B publication Critical patent/ZA200701972B/en

Links

229910052760 oxygen Inorganic materials 0.000 title claims description 13
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 title claims description 7
239000001301 oxygen Substances 0.000 title claims description 6
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 title description 12
229960003638 dopamine Drugs 0.000 title description 6
239000005557 antagonist Substances 0.000 title description 3
FKRLWISOOAJICU-UHFFFAOYSA-N n-phenyldiazepane-1-carboxamide Chemical class C1CCCCNN1C(=O)NC1=CC=CC=C1 FKRLWISOOAJICU-UHFFFAOYSA-N 0.000 title 1
YEQDVKYOHVLZPU-UHFFFAOYSA-N n-phenylpiperazine-1-carboxamide Chemical class C1CNCCN1C(=O)NC1=CC=CC=C1 YEQDVKYOHVLZPU-UHFFFAOYSA-N 0.000 title 1
150000001875 compounds Chemical class 0.000 claims description 54
125000005605 benzo group Chemical group 0.000 claims description 49
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 47
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 41
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 35
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 35
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 35
229910052794 bromium Inorganic materials 0.000 claims description 35
229910052801 chlorine Inorganic materials 0.000 claims description 35
239000000460 chlorine Substances 0.000 claims description 35
229910052731 fluorine Inorganic materials 0.000 claims description 35
239000011737 fluorine Substances 0.000 claims description 35
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 32
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 30
229910052739 hydrogen Inorganic materials 0.000 claims description 27
239000001257 hydrogen Substances 0.000 claims description 27
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 27
125000000217 alkyl group Chemical group 0.000 claims description 23
125000001153 fluoro group Chemical group F* 0.000 claims description 20
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 15
229910052736 halogen Inorganic materials 0.000 claims description 15
150000002367 halogens Chemical class 0.000 claims description 15
125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 14
238000011282 treatment Methods 0.000 claims description 12
125000003545 alkoxy group Chemical group 0.000 claims description 11
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 10
125000006193 alkinyl group Chemical group 0.000 claims description 10
125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 9
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 9
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
125000003884 phenylalkyl group Chemical group 0.000 claims description 8
125000004093 cyano group Chemical group *C#N 0.000 claims description 7
-1 cyano, nitro, amino, carboxy, sulfo, sulfamoyl Chemical group 0.000 claims description 7
208000035475 disorder Diseases 0.000 claims description 7
239000000825 pharmaceutical preparation Substances 0.000 claims description 7
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 7
229920006395 saturated elastomer Polymers 0.000 claims description 7
208000011580 syndromic disease Diseases 0.000 claims description 7
125000004448 alkyl carbonyl group Chemical group 0.000 claims description 6
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 6
239000003814 drug Substances 0.000 claims description 6
208000018737 Parkinson disease Diseases 0.000 claims description 5
125000005037 alkyl phenyl group Chemical group 0.000 claims description 5
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 5
230000006735 deficit Effects 0.000 claims description 5
229940079593 drug Drugs 0.000 claims description 5
201000000980 schizophrenia Diseases 0.000 claims description 5
125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims description 5
229910052717 sulfur Inorganic materials 0.000 claims description 5
125000004750 (C1-C6) alkylaminosulfonyl group Chemical group 0.000 claims description 4
125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims description 4
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
208000020401 Depressive disease Diseases 0.000 claims description 4
208000005793 Restless legs syndrome Diseases 0.000 claims description 4
125000003342 alkenyl group Chemical group 0.000 claims description 4
125000004471 alkyl aminosulfonyl group Chemical group 0.000 claims description 4
125000004656 alkyl sulfonylamino group Chemical group 0.000 claims description 4
125000004414 alkyl thio group Chemical group 0.000 claims description 4
125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 4
125000001183 hydrocarbyl group Chemical group 0.000 claims description 4
208000031424 hyperprolactinemia Diseases 0.000 claims description 4
125000004043 oxo group Chemical group O=* 0.000 claims description 4
229930195734 saturated hydrocarbon Natural products 0.000 claims description 4
125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 claims description 4
206010003805 Autism Diseases 0.000 claims description 3
208000020706 Autistic disease Diseases 0.000 claims description 3
208000010412 Glaucoma Diseases 0.000 claims description 3
125000004432 carbon atom Chemical group C* 0.000 claims description 3
210000003169 central nervous system Anatomy 0.000 claims description 3
208000010877 cognitive disease Diseases 0.000 claims description 3
238000000034 method Methods 0.000 claims description 3
125000006261 methyl amino sulfonyl group Chemical group [H]N(C([H])([H])[H])S(*)(=O)=O 0.000 claims description 3
125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 2
125000004845 (C1-C6) alkylsulfonylamino group Chemical group 0.000 claims description 2
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 2
239000012458 free base Substances 0.000 claims description 2
150000003839 salts Chemical class 0.000 claims description 2
229930195735 unsaturated hydrocarbon Natural products 0.000 claims description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 claims 20
150000002431 hydrogen Chemical class 0.000 claims 7
238000004519 manufacturing process Methods 0.000 claims 5
206010046543 Urinary incontinence Diseases 0.000 claims 3
208000019901 Anxiety disease Diseases 0.000 claims 2
208000010228 Erectile Dysfunction Diseases 0.000 claims 2
241000124008 Mammalia Species 0.000 claims 2
206010028813 Nausea Diseases 0.000 claims 2
208000028017 Psychotic disease Diseases 0.000 claims 2
208000006011 Stroke Diseases 0.000 claims 2
208000000323 Tourette Syndrome Diseases 0.000 claims 2
208000016620 Tourette disease Diseases 0.000 claims 2
208000026723 Urinary tract disease Diseases 0.000 claims 2
201000001881 impotence Diseases 0.000 claims 2
230000008693 nausea Effects 0.000 claims 2
208000014001 urinary system disease Diseases 0.000 claims 2
239000002671 adjuvant Substances 0.000 claims 1
208000013403 hyperactivity Diseases 0.000 claims 1
239000003176 neuroleptic agent Substances 0.000 claims 1
239000008194 pharmaceutical composition Substances 0.000 claims 1
125000004356 hydroxy functional group Chemical group O* 0.000 description 29
239000003446 ligand Substances 0.000 description 7
108050004812 Dopamine receptor Proteins 0.000 description 6
102000015554 Dopamine receptor Human genes 0.000 description 6
108020003175 receptors Proteins 0.000 description 6
102000005962 receptors Human genes 0.000 description 6
SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 4
230000000694 effects Effects 0.000 description 4
208000012661 Dyskinesia Diseases 0.000 description 3
238000011835 investigation Methods 0.000 description 3
230000004770 neurodegeneration Effects 0.000 description 3
239000004031 partial agonist Substances 0.000 description 3
YZTJYBJCZXZGCT-UHFFFAOYSA-N phenylpiperazine Chemical compound C1CNCCN1C1=CC=CC=C1 YZTJYBJCZXZGCT-UHFFFAOYSA-N 0.000 description 3
239000000126 substance Substances 0.000 description 3
125000001424 substituent group Chemical group 0.000 description 3
QHKJIJXBJCOABP-UHFFFAOYSA-N 1-benzofuran-2-carboxamide Chemical compound C1=CC=C2OC(C(=O)N)=CC2=C1 QHKJIJXBJCOABP-UHFFFAOYSA-N 0.000 description 2
PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 2
125000006852 aliphatic spacer Chemical group 0.000 description 2
150000003857 carboxamides Chemical class 0.000 description 2
PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 2
RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 2
208000015122 neurodegenerative disease Diseases 0.000 description 2
230000019491 signal transduction Effects 0.000 description 2
PLRACCBDVIHHLZ-UHFFFAOYSA-N 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Chemical compound C1N(C)CCC(C=2C=CC=CC=2)=C1 PLRACCBDVIHHLZ-UHFFFAOYSA-N 0.000 description 1
XXOQJWXDRPURJK-UHFFFAOYSA-N 2,3,4,5-tetrahydro-1-benzoxepine Chemical compound O1CCCCC2=CC=CC=C21 XXOQJWXDRPURJK-UHFFFAOYSA-N 0.000 description 1
SLQITXDMNLWAEY-UHFFFAOYSA-N 3-phenyl-2-piperazin-1-ylnaphthalene-1-carboxamide Chemical compound C=1C=CC=CC=1C1=CC2=CC=CC=C2C(C(=O)N)=C1N1CCNCC1 SLQITXDMNLWAEY-UHFFFAOYSA-N 0.000 description 1
102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 description 1
206010001540 Akathisia Diseases 0.000 description 1
206010008531 Chills Diseases 0.000 description 1
208000022497 Cocaine-Related disease Diseases 0.000 description 1
101150049660 DRD2 gene Proteins 0.000 description 1
102000004073 Dopamine D3 Receptors Human genes 0.000 description 1
108090000525 Dopamine D3 Receptors Proteins 0.000 description 1
208000014094 Dystonic disease Diseases 0.000 description 1
102000017911 HTR1A Human genes 0.000 description 1
101150015707 HTR1A gene Proteins 0.000 description 1
101000822895 Homo sapiens 5-hydroxytryptamine receptor 1A Proteins 0.000 description 1
WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
101001135571 Mus musculus Tyrosine-protein phosphatase non-receptor type 2 Proteins 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000001800 adrenalinergic effect Effects 0.000 description 1
239000000556 agonist Substances 0.000 description 1
238000010171 animal model Methods 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
210000004227 basal ganglia Anatomy 0.000 description 1
229940054066 benzamide antipsychotics Drugs 0.000 description 1
150000003936 benzamides Chemical class 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
208000015114 central nervous system disease Diseases 0.000 description 1
VZWXIQHBIQLMPN-UHFFFAOYSA-N chromane Chemical compound C1=CC=C2CCCOC2=C1 VZWXIQHBIQLMPN-UHFFFAOYSA-N 0.000 description 1
201000006145 cocaine dependence Diseases 0.000 description 1
230000019771 cognition Effects 0.000 description 1
QPMLSUSACCOBDK-UHFFFAOYSA-N diazepane Chemical group C1CCNNCC1 QPMLSUSACCOBDK-UHFFFAOYSA-N 0.000 description 1
201000010099 disease Diseases 0.000 description 1
206010013663 drug dependence Diseases 0.000 description 1
208000010118 dystonia Diseases 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
230000010491 emotional process Effects 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
229940125425 inverse agonist Drugs 0.000 description 1
238000012153 long-term therapy Methods 0.000 description 1
238000011866 long-term treatment Methods 0.000 description 1
230000001095 motoneuron effect Effects 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
230000007121 neuropathological change Effects 0.000 description 1
230000004112 neuroprotection Effects 0.000 description 1
230000000324 neuroprotective effect Effects 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
125000004193 piperazinyl group Chemical group 0.000 description 1
208000020016 psychiatric disease Diseases 0.000 description 1
230000002295 serotoninergic effect Effects 0.000 description 1
230000008054 signal transmission Effects 0.000 description 1
125000006850 spacer group Chemical group 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
210000001635 urinary tract Anatomy 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Psychiatry (AREA)
Ophthalmology & Optometry (AREA)
Urology & Nephrology (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Diabetes (AREA)
Gynecology & Obstetrics (AREA)
Hematology (AREA)
Cardiology (AREA)
Pain & Pain Management (AREA)
Addiction (AREA)
Anesthesiology (AREA)
Heart & Thoracic Surgery (AREA)
Otolaryngology (AREA)
Vascular Medicine (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Polyesters Or Polycarbonates (AREA)
External Artificial Organs (AREA)

ZA200701972A 2004-12-30 2007-01-18 Phenyl diazepane carboxamides and annelated phenyl piperazine carboxamides containing oxygen and used as dopamine D3 antagonists ZA200701972B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE102004063797A DE102004063797A1 (de)	2004-12-30	2004-12-30	Sauerstoffhaltige annelierte Phenylpiperazin- und Phenyldiazepancarboxamide

Publications (1)

Publication Number	Publication Date
ZA200701972B true ZA200701972B (en)	2008-04-30

Family

ID=36102609

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200701972A ZA200701972B (en)	2004-12-30	2007-01-18	Phenyl diazepane carboxamides and annelated phenyl piperazine carboxamides containing oxygen and used as dopamine D3 antagonists

Country Status (21)

Country	Link
US (1)	US20080194539A1 (fr)
EP (1)	EP1761524B1 (fr)
JP (1)	JP2008526700A (fr)
KR (1)	KR20070102673A (fr)
CN (1)	CN101027294A (fr)
AU (1)	AU2005324107A1 (fr)
BR (1)	BRPI0519485A2 (fr)
CA (1)	CA2576332A1 (fr)
DE (2)	DE102004063797A1 (fr)
DK (1)	DK1761524T3 (fr)
EA (1)	EA200701366A1 (fr)
ES (1)	ES2297767T3 (fr)
HR (1)	HRP20080075T3 (fr)
IL (1)	IL180763A0 (fr)
MX (1)	MX2007006369A (fr)
NO (1)	NO20072587L (fr)
PL (1)	PL1761524T3 (fr)
PT (1)	PT1761524E (fr)
SI (1)	SI1761524T1 (fr)
WO (1)	WO2006072430A1 (fr)
ZA (1)	ZA200701972B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN102264733B (zh) *	2008-10-10	2014-07-30	中国人民解放军军事医学科学院毒物药物研究所	新型多巴胺d3受体配体，其制备方法及其医药用途
US9227944B2 (en)	2008-10-10	2016-01-05	Institute Of Pharmacology And Toxicology Academy Of Military Science P.L.A. China	Dopamine D3 receptor ligands and preparation and medical uses of the same
EP2406243B1 (fr) *	2009-03-10	2014-05-07	Takeda Pharmaceutical Company Limited	Dérivés de benzofurane
WO2012137227A2 (fr) *	2011-04-08	2012-10-11	Laurus Labs Private Limited	Formes solides de composés antirétroviraux, procédé de préparation correspondant et composition pharmaceutique de ces composés

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL90279A (en) *	1988-05-24	1995-03-30	American Home Prod	Piperazinyl carboxamide derivatives, their preparation and pharmaceutical com¦ositions containing them
IL92544A0 (en) *	1988-12-08	1990-08-31	Duphar Int Res	Piperazine derivatives,their preparation and pharmaceutical compositions containing them
DE4127849A1 (de) *	1991-08-22	1993-02-25	Merck Patent Gmbh	Benzodioxanderivate
DE4333254A1 (de) *	1993-09-30	1995-04-06	Merck Patent Gmbh	Piperidine und Piperazine
KR100545329B1 (ko) *	1997-07-25	2006-01-24	하. 룬트벡 아크티에 셀스카브	인돌 및 2,3-디히드로인돌 유도체, 그들의 제조방법 및 사용
FR2781671A1 (fr) *	1998-07-28	2000-02-04	Synthelabo	Compositions pharmaceutiques contenant un inhibiteur de la recapture de la serotonine et leur application en therapeutique
AR022303A1 (es) *	1999-01-22	2002-09-04	Lundbeck & Co As H	Derivados de piperidina, tetrahidropiridina y piperazina, su preparacion y utilizacion
GB9905010D0 (en) *	1999-03-04	1999-04-28	Merck Sharp & Dohme	Therapeutic agents
ES2188344B1 (es) *	2000-11-29	2004-09-16	Laboratorios Vita, S.A.	Compuestos derivados de benzotiofeno, su procedimiento de obtencion y utilizacion de los mismos.
HUP0103987A3 (en) *	2001-09-28	2004-11-29	Richter Gedeon Vegyeszet	Phenylpiperazinylalkyl carboxylic acid amid derivatives, process for their preparation, pharmaceutical compositions containing them and their intermediates
KR20050075281A (ko) *	2002-07-04	2005-07-20	쉬바르츠파르마에이지	씨엔에스 질병의 치료를 위한 도파민-디3 리간드로서헤테로아렌 카복스아미드의 용도
AU2003267201B2 (en) *	2002-09-14	2009-04-23	The Gov't Of The U.S.A. As Represented By The Secretary Of The Department Of Health And Human Services	Structurally rigid dopamine D3 receptor selective ligands and process for making them
DE10259244A1 (de) *	2002-12-17	2004-07-01	Merck Patent Gmbh	N-(Indolethyl-)cycloamin-Verbindungen
WO2004082686A2 (fr) *	2003-03-13	2004-09-30	Dynogen Pharmaceuticals, Inc.	Methodes d'utilisation de composes presentant des activites combinees 5-ht1a et ssri, en fonction des besoins, pour traiter dysfonction sexuelle

2004
- 2004-12-30 DE DE102004063797A patent/DE102004063797A1/de not_active Ceased
2005
- 2005-12-27 EP EP05823871A patent/EP1761524B1/fr not_active Expired - Lifetime
- 2005-12-27 DK DK05823871T patent/DK1761524T3/da active
- 2005-12-27 PT PT05823871T patent/PT1761524E/pt unknown
- 2005-12-27 JP JP2007548748A patent/JP2008526700A/ja active Pending
- 2005-12-27 KR KR1020077014615A patent/KR20070102673A/ko not_active Withdrawn
- 2005-12-27 CN CNA2005800324230A patent/CN101027294A/zh active Pending
- 2005-12-27 AU AU2005324107A patent/AU2005324107A1/en not_active Abandoned
- 2005-12-27 HR HR20080075T patent/HRP20080075T3/xx unknown
- 2005-12-27 MX MX2007006369A patent/MX2007006369A/es not_active Application Discontinuation
- 2005-12-27 BR BRPI0519485-7A patent/BRPI0519485A2/pt not_active Application Discontinuation
- 2005-12-27 US US11/794,386 patent/US20080194539A1/en not_active Abandoned
- 2005-12-27 SI SI200530145T patent/SI1761524T1/sl unknown
- 2005-12-27 ES ES05823871T patent/ES2297767T3/es not_active Expired - Lifetime
- 2005-12-27 PL PL05823871T patent/PL1761524T3/pl unknown
- 2005-12-27 EA EA200701366A patent/EA200701366A1/ru unknown
- 2005-12-27 WO PCT/EP2005/014047 patent/WO2006072430A1/fr not_active Ceased
- 2005-12-27 CA CA002576332A patent/CA2576332A1/fr not_active Abandoned
- 2005-12-27 DE DE502005002058T patent/DE502005002058D1/de not_active Expired - Fee Related
2007
- 2007-01-17 IL IL180763A patent/IL180763A0/en unknown
- 2007-01-18 ZA ZA200701972A patent/ZA200701972B/en unknown
- 2007-05-21 NO NO20072587A patent/NO20072587L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
EP1761524A1 (fr)	2007-03-14
CA2576332A1 (fr)	2006-07-13
IL180763A0 (en)	2007-06-03
BRPI0519485A2 (pt)	2009-02-03
PL1761524T3 (pl)	2008-04-30
MX2007006369A (es)	2007-07-11
NO20072587L (no)	2007-05-21
JP2008526700A (ja)	2008-07-24
DE102004063797A1 (de)	2006-07-13
WO2006072430A1 (fr)	2006-07-13
DK1761524T3 (da)	2008-04-07
PT1761524E (pt)	2008-02-21
AU2005324107A1 (en)	2006-07-13
HRP20080075T3 (hr)	2008-03-31
SI1761524T1 (sl)	2008-04-30
EP1761524B1 (fr)	2007-11-21
CN101027294A (zh)	2007-08-29
DE502005002058D1 (de)	2008-01-03
EA200701366A1 (ru)	2008-02-28
KR20070102673A (ko)	2007-10-19
HK1100845A1 (en)	2007-09-28
ES2297767T3 (es)	2008-05-01
AU2005324107A2 (en)	2006-07-13
US20080194539A1 (en)	2008-08-14

Publication	Publication Date	Title
AU2002237654B2 (en)	2005-07-28	Piperazine derivatives, their preparation and their use for treating central nervous system (CNS) disorders
TW200718692A (en)	2007-05-16	Dihydrobenzofuran derivatives and uses thereof
TW200720266A (en)	2007-06-01	Benzodioxane and benzodioxolan derivatives and uses thereof
MA30991B1 (fr)	2009-12-01	Utilisation de dérivés du benzamide comme agonistes des récepteurs ep4
MX2015015893A (es)	2016-03-04	2-fenilimidazo[1,2-a]pirimidinas como agentes formadores de imagen.
TW200716595A (en)	2007-05-01	Chromane and chromene derivatives and uses thereof
TW200719886A (en)	2007-06-01	Dihydrobenzofuran derivatives and uses thereof
SG155938A1 (en)	2009-10-29	Novel pyridinone derivatives and their use as positive allosteric modulators of mglur2-receptors
WO2008117269A3 (fr)	2008-12-31	Composés hétérocycliques comme agents sérotoninergiques et dopaminergiques et leurs utilisations
ZA200701972B (en)	2008-04-30	Phenyl diazepane carboxamides and annelated phenyl piperazine carboxamides containing oxygen and used as dopamine D3 antagonists
ZA200405733B (en)	2005-10-19	Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands.
AU2002237654A1 (en)	2002-08-15	Piperazine derivatives, their preparation and their use for treating central nervous system (CNS) disorders
BG64387B1 (bg)	2004-12-30	Халоген заместени тетрациклени производни на тетрахидрофуран
RU2006105779A (ru)	2007-09-20	Индол-5-ильные сульфонамидные производные, их получение и их применение в качестве модуляторов 5-нт-6
NO20064892L (no)	2006-12-13	Heterosykliske fenylpropan-2-olderivater og relaterte forbindelser som modulatorer av norepinefrin (NE) og serotonin (5-HT) aktivitet og monoamin-gjenopptak for behandling av
WO2008052088A8 (fr)	2008-09-25	Dérivés de chromane, synthèse de ceux-ci et leurs intermédiaires
CN1119189A (zh)	1996-03-27	新的苯并吡喃化合物，它们的制备方法和含有它们的药物组合物
AU2003262931A1 (en)	2004-03-19	Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma
NZ592478A (en)	2012-08-31	Process for synthesis of amino-methyl tetraline derivatives
WO2007123941A3 (fr)	2008-01-31	Dérivés de chromane et de chromène et leurs utilisations
Lin et al.	1993	Centrally acting serotonergic and dopaminergic agents. 1. Synthesis and structure-activity relationships of 2, 3, 3a, 4, 5, 9b-hexahydro-1H-benz [e] indole derivatives
MXPA05013084A (es)	2006-03-02	Preparacion de quinoxalinas sustituidas a partir de la dianilina con 2,3-dihidroxi-1,4-dioxano.
CN1371365A (zh)	2002-09-25	哌啶醇
RU2006141835A (ru)	2008-06-10	Тетразамещенные производные имидазола в качестве модуляторов рецепторов св1 каннабиноидов с высокой селективностью к подтипам рецепторов св1/св2
CA2509225A1 (fr)	2004-06-24	Derives d'indol et leur utilisation comme ligands 5-ht